Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or over~* Definite Enterococcal endocarditis, as defined by modified Duke criteria~* Able to complete follow-up 3 and 6 weeks following completion of intravenous antibiotic therapy~Exclusion Criteria:~* Pregnancy or breast feeding~* Creatine phosphokinase levels over two times the upper limit of normal~* Renal insufficiency or dialysis requirement.~* Presence of chronic indwelling bloodstream catheters or foreign body devices suspected as primary or secondary sites of enterococcal infection unamenable to removal or replacement~* Inability to discontinue or abstain from use of a HMG CoA reductase inhibitor during the study period.~* Hypersensitivity to any of the study medications.~* Any condition that, in the investigator's opinion, may interfere with protocol compliance including, but not limited to, active substance abuse and/or dementia.~* Prosthetic valve endocarditis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daptomycin adjunctive group (Type: EXPERIMENTAL): Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
- standard of care (Type: NO_INTERVENTION): Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician

Based on this trial design, predict the completion outcome and termination type (if applicable).